MedTrace Logo

Study of SPARC1103 in Subjects With Spasticity

NCT02027025 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2019-05-03

Study results available
· View outcomes & findings →

Summary

Study of SPARC1103 in subjects with spasticity

Conditions

  • Spasticity

Interventions

DRUG

SPARC1103 low dose

once daily

DRUG

SPARC1103 high dose

once daily

DRUG

SPARC Placebo

Sponsors & Collaborators

  • Sun Pharma Advanced Research Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-21
Primary Completion
2017-04-28
Completion
2017-04-28

Countries

  • United States
  • Russia
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02027025 on ClinicalTrials.gov